Source:http://linkedlifedata.com/resource/pubmed/id/17657489
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-11-20
|
| pubmed:abstractText |
The collapsin response mediator protein 5 (CRMP5) antibody is usually associated with paraneoplastic neurological syndrome (PNS) and small-cell lung cancer (SCLC) or thymoma. The objective of this study was to assess the frequency of CRMP5 antibodies in patients with such tumours and to see if the presence of antibodies was associated with prognosis in these cancers. A multi-well adapted immunoprecipitation assay using radiolabelled recombinant CRMP5 protein, produced by coupled in vitro transcription/translation, was used for the detection of CRMP5 antibodies. Sera from 200 patients with SCLC, 73 patients with thymoma and myasthenia gravis (MG) and from 300 healthy blood donors were examined for CRMP5 antibodies. Positive sera were also examined by immunofluorescence and immune blots. The serological results were compared with disease severity of the patients with thymoma or SCLC. CRMP5 antibodies were detected in 10/200 (5%) of the SCLC, 9/73 (12%) of the thymomas and in 2/300 (0.6%) of the healthy controls by immunoprecipitation. The antibodies were less frequently detected by immunofluorescence or immune blots. There was no significant correlation between CRMP5 antibodies and disease severity. CRMP5 antibodies are more than twice as frequent, and the antibody levels are higher in patients with thymoma and MG than in patients with SCLC. The antibodies are correlated to these tumours, but not to disease severity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0340-7004
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
57
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
227-32
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17657489-Adult,
pubmed-meshheading:17657489-Aged,
pubmed-meshheading:17657489-Antibodies,
pubmed-meshheading:17657489-Carcinoma, Small Cell,
pubmed-meshheading:17657489-Female,
pubmed-meshheading:17657489-Fluorescent Antibody Technique,
pubmed-meshheading:17657489-Humans,
pubmed-meshheading:17657489-Immunoblotting,
pubmed-meshheading:17657489-Immunoprecipitation,
pubmed-meshheading:17657489-Kaplan-Meier Estimate,
pubmed-meshheading:17657489-Lung Neoplasms,
pubmed-meshheading:17657489-Male,
pubmed-meshheading:17657489-Middle Aged,
pubmed-meshheading:17657489-Myasthenia Gravis,
pubmed-meshheading:17657489-Nerve Tissue Proteins,
pubmed-meshheading:17657489-Prognosis,
pubmed-meshheading:17657489-Sensitivity and Specificity,
pubmed-meshheading:17657489-Thymoma,
pubmed-meshheading:17657489-Thymus Neoplasms,
pubmed-meshheading:17657489-Tumor Markers, Biological
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
CRMP5 antibodies in patients with small-cell lung cancer or thymoma.
|
| pubmed:affiliation |
Department of Clinical Medicine, University of Bergen, Bergen, Norway. sissel.monstad@helse-bergen.no
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|